Loading...

Medicine Man Technologies

OTCPK:MDCL
Snowflake Description

Excellent balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MDCL
OTCPK
$104M
Market Cap
  1. Home
  2. US
  3. Commercial Services
Company description

Medicine Man Technologies, Inc. provides cultivation consulting services for cannabis growing technologies and methodologies. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Medicine Man Technologies has significant price volatility in the past 3 months.
MDCL Share Price and Events
7 Day Returns
40.2%
OTCPK:MDCL
0.1%
US Commercial Services
-2.1%
US Market
1 Year Returns
96.8%
OTCPK:MDCL
12.8%
US Commercial Services
1.3%
US Market
MDCL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medicine Man Technologies (MDCL) 40.2% 19.7% 94.7% 96.8% 105.6% -
US Commercial Services 0.1% 0.3% 5.4% 12.8% 50% 72.2%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • MDCL outperformed the Commercial Services industry which returned 12.8% over the past year.
  • MDCL outperformed the Market in United States of America which returned 1.3% over the past year.
Price Volatility
MDCL
Industry
5yr Volatility vs Market

MDCL Value

 Is Medicine Man Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Medicine Man Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Medicine Man Technologies.

OTCPK:MDCL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:MDCL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Commercial Services Unlevered Beta Simply Wall St/ S&P Global 0.72
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.718 (1 + (1- 21%) (0.23%))
0.812
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.812 * 5.96%)
7.57%

Discounted Cash Flow Calculation for OTCPK:MDCL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Medicine Man Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:MDCL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.57%)
2019 3.26 Est @ 83.37% 3.03
2020 5.19 Est @ 59.18% 4.49
2021 7.38 Est @ 42.24% 5.93
2022 9.63 Est @ 30.39% 7.19
2023 11.75 Est @ 22.09% 8.16
2024 13.67 Est @ 16.28% 8.82
2025 15.34 Est @ 12.22% 9.20
2026 16.77 Est @ 9.37% 9.36
2027 18.01 Est @ 7.38% 9.34
2028 19.09 Est @ 5.98% 9.20
Present value of next 10 years cash flows $74.73
OTCPK:MDCL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $19.09 × (1 + 2.73%) ÷ (7.57% – 2.73%)
$405.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $405.38 ÷ (1 + 7.57%)10
$195.45
OTCPK:MDCL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $74.73 + $195.45
$270.18
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $270.18 / 27.99
$9.65
OTCPK:MDCL Discount to Share Price
Calculation Result
Value per share (USD) From above. $9.65
Current discount Discount to share price of $3.70
= -1 x ($3.70 - $9.65) / $9.65
61.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Medicine Man Technologies is available for.
Intrinsic value
>50%
Share price is $3.7 vs Future cash flow value of $9.65
Current Discount Checks
For Medicine Man Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Medicine Man Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Medicine Man Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medicine Man Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medicine Man Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:MDCL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.08
OTCPK:MDCL Share Price ** OTCPK (2019-05-24) in USD $3.7
United States of America Commercial Services Industry PE Ratio Median Figure of 48 Publicly-Listed Commercial Services Companies 22.6x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medicine Man Technologies.

OTCPK:MDCL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:MDCL Share Price ÷ EPS (both in USD)

= 3.7 ÷ -0.08

-48.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicine Man Technologies is loss making, we can't compare its value to the US Commercial Services industry average.
  • Medicine Man Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Medicine Man Technologies's expected growth come at a high price?
Raw Data
OTCPK:MDCL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -48.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Commercial Services Industry PEG Ratio Median Figure of 34 Publicly-Listed Commercial Services Companies 1.73x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medicine Man Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medicine Man Technologies's assets?
Raw Data
OTCPK:MDCL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.54
OTCPK:MDCL Share Price * OTCPK (2019-05-24) in USD $3.7
United States of America Commercial Services Industry PB Ratio Median Figure of 88 Publicly-Listed Commercial Services Companies 1.88x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
OTCPK:MDCL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:MDCL Share Price ÷ Book Value per Share (both in USD)

= 3.7 ÷ 0.54

6.89x

* Primary Listing of Medicine Man Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicine Man Technologies is overvalued based on assets compared to the US Commercial Services industry average.
X
Value checks
We assess Medicine Man Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. Medicine Man Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MDCL Future Performance

 How is Medicine Man Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicine Man Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.9%
Expected Commercial Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medicine Man Technologies expected to grow at an attractive rate?
  • Unable to compare Medicine Man Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medicine Man Technologies's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Medicine Man Technologies's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:MDCL Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 14.9%
United States of America Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:MDCL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:MDCL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
OTCPK:MDCL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 9 2 -2
2018-12-31 8 1 1
2018-09-30 7 4 5
2018-06-30 5 -1 -1
2018-03-31 4 -1 -5
2017-12-31 3 -1 -5
2017-09-30 2 -1 -6
2017-06-30 2 -1 -6
2017-03-31 1 -1 -1
2016-12-31 1 -1 -1
2016-09-30 1 0 0
2016-06-30 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medicine Man Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Medicine Man Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:MDCL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medicine Man Technologies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MDCL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
OTCPK:MDCL Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.08
2018-12-31 0.04
2018-09-30 0.17
2018-06-30 -0.03
2018-03-31 -0.21
2017-12-31 -0.23
2017-09-30 -0.32
2017-06-30 -0.55
2017-03-31 -0.12
2016-12-31 -0.14
2016-09-30 -0.02
2016-06-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medicine Man Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Medicine Man Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Medicine Man Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medicine Man Technologies's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medicine Man Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medicine Man Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MDCL Past Performance

  How has Medicine Man Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medicine Man Technologies's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medicine Man Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medicine Man Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medicine Man Technologies's 1-year growth to the US Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
Medicine Man Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medicine Man Technologies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MDCL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 8.66 -1.99 6.70
2018-12-31 7.86 0.95 4.89
2018-09-30 7.34 4.65 -0.16
2018-06-30 4.64 -0.79 -1.09
2018-03-31 4.12 -5.47 3.10
2017-12-31 3.48 -5.38 7.31
2017-09-30 2.40 -6.14 7.01
2017-06-30 1.71 -5.63 6.24
2017-03-31 0.97 -1.24 1.37
2016-12-31 0.63 -1.46 1.32
2016-09-30 0.82 -0.24 0.72
2016-06-30 0.83 -0.21 0.74
2016-03-31 0.93 -0.05 0.66
2015-12-31 0.84 0.09 0.54
2015-09-30 0.70 -0.05 0.52
2014-12-31 0.34 -0.04 0.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medicine Man Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medicine Man Technologies has efficiently used its assets last year compared to the US Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medicine Man Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medicine Man Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medicine Man Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MDCL Health

 How is Medicine Man Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medicine Man Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medicine Man Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medicine Man Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medicine Man Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 12.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medicine Man Technologies Company Filings, last reported 1 month ago.

OTCPK:MDCL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 15.35 0.24 0.70
2018-12-31 17.07 0.00 0.32
2018-09-30 20.73 0.00 0.53
2018-06-30 11.95 0.00 0.85
2018-03-31 10.76 0.00 0.38
2017-12-31 10.74 0.06 0.75
2017-09-30 10.40 0.73 0.93
2017-06-30 6.64 0.73 0.22
2017-03-31 -0.01 0.74 0.19
2016-12-31 -0.38 0.81 0.37
2016-09-30 0.29 0.15 0.11
2016-06-30 0.29 0.00 0.07
2016-03-31 0.40 0.00 0.32
2015-12-31 0.46 0.00 0.30
2015-09-30 0.51 0.00 0.39
2014-12-31 0.29 0.00 0.05
  • Medicine Man Technologies's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Medicine Man Technologies's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Medicine Man Technologies has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Medicine Man Technologies has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -63.8% per year.
X
Financial health checks
We assess Medicine Man Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medicine Man Technologies has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MDCL Dividends

 What is Medicine Man Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medicine Man Technologies dividends.
If you bought $2,000 of Medicine Man Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medicine Man Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medicine Man Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:MDCL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:MDCL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medicine Man Technologies has not reported any payouts.
  • Unable to verify if Medicine Man Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medicine Man Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medicine Man Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medicine Man Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medicine Man Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medicine Man Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MDCL Management

 What is the CEO of Medicine Man Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andy Williams
COMPENSATION $300,000
AGE 49
TENURE AS CEO 0.4 years
CEO Bio

Mr. Andrew Williams, also known as Andy, serves as the Managing Partner of MedPharm Holdings, LLC. He has been Chief Executive Officer of Medicine Man Technologies, Inc. since April 2019. Mr. Williams served as Interim Chief Executive Officer of Medicine Man Technologies, Inc. since December 3, 2018 until April 2019. He served as Chief Executive Officer of Medicine Man Technologies, Inc. from April 2014 to June 3, 2017. He is veteran of the US Army and served three years as a Cavalry Scout in the 3rd Infantry Division. He has worked in a wide range of manufacturing industries as an Industrial Engineer and in leadership positions. He is a Lifelong Entrepreneur. Mr. Williams served as the President of Medicine Man Technologies, Inc. since April 2014. He served as the President and Chief Executive Officer of Medicine Man Denver since September 2009. He served as a Project Portfolio Manager with Jeppesen, a Boeing Company from August 2006 to August 2010. Mr. Williams served as the Chairman of the Board of Medicine Man Technologies, Inc. since June 3, 2017 until December 3, 2018 and previously served as its Chairman of the Board until June 3, 2017. He serves as a Director of Medicine Man Technologies, Inc. Mr. Williams was in the US Army as a Calvary Scout from 1986 to 1989 and received an honorable discharge. Mr. Williams received a Bachelor of Science degree in Industrial Engineering from the University of Southern Colorado in 1995.

CEO Compensation
  • Andy's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Andy's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Medicine Man Technologies management team in years:

0.3
Average Tenure
48
Average Age
  • The average tenure for the Medicine Man Technologies management team is less than 2 years, this suggests a new team.
Management Team

Paul Dickman

TITLE
Chairman
COMPENSATION
$111K
AGE
38
TENURE
0.1 yrs

Andy Williams

TITLE
Co-Founder
COMPENSATION
$300K
AGE
49
TENURE
0.4 yrs

Joe Puglise

TITLE
COO & Director
COMPENSATION
$300K
AGE
48
TENURE
0.4 yrs

Joshua Haupt

TITLE
Chief Revenue Officer
COMPENSATION
$168K
AGE
31

Jim Toreson

TITLE
Consultant
COMPENSATION
$106K
AGE
76
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Medicine Man Technologies board of directors in years:

0.4
Average Tenure
48.5
Average Age
  • The average tenure for the Medicine Man Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Dickman

TITLE
Chairman
COMPENSATION
$111K
AGE
38
TENURE
0.4 yrs

Andy Williams

TITLE
Co-Founder
COMPENSATION
$300K
AGE
49

Joe Puglise

TITLE
COO & Director
COMPENSATION
$300K
AGE
48
TENURE
0.3 yrs

Charles Haupt

TITLE
Director
COMPENSATION
$106K
AGE
55
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • Medicine Man Technologies insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Apr 19 Sell Charles Haupt Individual 28. Mar 19 28. Mar 19 -50,000 $1.25 $-62,500
05. Apr 19 Sell Joshua Haupt Individual 08. Mar 19 25. Mar 19 -400,000 $1.50 $-500,000
29. Mar 19 Sell Jonathan Sandberg Individual 22. Mar 19 26. Mar 19 -60,000 $2.07 $-123,508
26. Mar 19 Sell Joshua Haupt Individual 06. Mar 19 15. Mar 19 -200,000 $1.87 $-366,435
22. Feb 19 Sell Joshua Haupt Individual 20. Feb 19 20. Feb 19 -200,000 $1.35 $-270,000
22. Jan 19 Sell Jonathan Sandberg Individual 17. Jan 19 17. Jan 19 -25,000 $1.63 $-40,386
10. Jan 19 Sell Andrew Williams Individual 03. Jan 19 03. Jan 19 -229,000 $1.00 $-229,000
03. Jul 18 Sell Andrew Williams Individual 01. Jun 18 29. Jun 18 -220,830 $1.84 $-371,191
X
Management checks
We assess Medicine Man Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medicine Man Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MDCL News

Simply Wall St News

MDCL Company Info

Description

Medicine Man Technologies, Inc. provides cultivation consulting services for cannabis growing technologies and methodologies. The company also provides licensing and seminar services. In addition, it engages in retail operations of cannabis products. The company was founded in 2014 and is based in Denver, Colorado.

Details
Name: Medicine Man Technologies, Inc.
MDCL
Exchange: OTCPK
Founded: 2014
$103,544,862
27,985,098
Website: http://www.medicinemantechnologies.com
Address: Medicine Man Technologies, Inc.
4880 Havana Street,
Suite 201,
Denver,
Colorado, 80239,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK MDCL Common Stock Pink Sheets LLC US USD 24. Dec 2015
Number of employees
Current staff
Staff numbers
25
Medicine Man Technologies employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:47
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2018/03/27
Last earnings filing: 2019/05/20
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.